Figure S1. Expression of miR-140-5p in HMCs/293 in different treatment groups. (A) Expression of miR-140-5p in HMCs that transfected with miR-140-5p inhibitor or NC was detected by RT-qPCR. (B) Expression of miR-140-5p in HMCs that transfected with miR-140-5p mimic/mut or NC was detected by RT-qPCR. (C) Expression of miR-140-5p in 293 transfected with miR-140-5p mimic/mut or NC was detected by RT-qPCR. ****P<0.0001. miR, microRNA; HMCs, human mesangial cells; NC, negative control; RT-qPCR, reverse transcription-quantitative PCR; mut, mutant.




Figure S2. Expression of DACH1 in HMCs in different treatment groups. (A) Expression of DACH1 in HMCs that cultured with pIgA-IgAN or pIgA-control was detected by RT-qPCR. (B) RT-qPCR analysis for DACH1 in HMCs infected with DACH1 or control lentivirus (pCDH). (C) HMCs were transfected with 10 miRNA mimics (20 nM) and NC, RT-qPCR was performed at 48 h after transfection, when miR-140-3p was transfected into HMCs, the mRNA and protein expression of DACH1 was decreased. ***P<0.001, NC vs. miR-140-3p; *P<0.05 NC vs. miR-1246/miR-1290/miR-150*. DACH1, dachshund family transcription factor 1; HMCs, human mesangial cells; pIgA, polymeric IgA; IgAN, immunoglobulin A nephropathy; RT-qPCR, reverse transcription-quantitative PCR; pCDH, pCDH-CMV-MCS-puro; NC, negative control.

